Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ZF0901 in Healthy Children
NCT04865497Phase 2Completed
- Sponsor
- Zhifei Green Bamboo
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Shigella flexneri-sonnei bivalent conjugate vaccine in shigellosis (4 arms), sponsored by Zhifei Green Bamboo. Primary endpoints: Incidence of adverse events at 30 days and Antibody positive rate at 30 days. Started Jan 2019; status: completed.
02
Drugs
Shigella flexneri-sonnei bivalent conjugate vaccine
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT04865497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04865497.